Navigation Links
ETEX Corporation Announces FDA Clearance of Small Size Beta-bsm(TM) Injectable Paste and Gamma-bsm(TM) Moldable Putty
Date:4/27/2009

CAMBRIDGE, Mass., April 27 /PRNewswire/ -- ETEX Corporation, a leading orthopaedic biomaterials company, announced today FDA 510k clearance of 1cc and 2.5cc sizes of Beta-bsm(TM) Injectable Paste and Gamma-bsm(TM) Moldable Putty to complement the existing 5cc and 10cc sizes. Both products are bone substitute materials based on ETEX's proprietary nanocrystalline calcium phosphate technology.

(Logo: http://www.newscom.com/cgi-bin/prnh/20080424/NETH117LOGO )

Beta-bsm(TM) and Gamma-bsm(TM) set hard to provide an optimal osteoconductive scaffold that mimics the nanocrystalline structure of human bone. Smaller sizes were developed in direct response to the needs of the small bone market. Both hand and foot/ankle surgeons requested user friendly moldable and injectable materials that set fast, are drillable, provide high compressive strength and remodel into bone over time.

Beta-bsm(TM) Injectable Paste and Gamma-bsm(TM) Moldable Putty are intended for use in filling bone voids or defects of the skeletal system (including extremities, pelvis, and spine) that are not intrinsic to the stability of the bone structure. ETEX's rapidly expanding product portfolio, including EquivaBone(TM), a hard-setting, certified osteoinductive product, is marketed through a growing independent distribution network.

Brian Ennis, CEO of ETEX Corporation, comments, "ETEX is proud of our product development approach, driven by direct customer input. We are excited to offer state of the art bone graft substitutes, formulated for optimal performance and patient outcomes, in sizes complimentary to extremity surgery."

About ETEX Corporation

Established in 1989, ETEX Corporation develops, manufactures and commercializes calcium phosphate-based biomaterials for improved orthopedic clinical outcomes. A leader in bioresorbable bone substitute materials, ETEX focuses on expanding applications through combinations with cells, biologics, or therapeutic agents delivered in minimally invasive and easy to use systems. For more information, visit www.etexcorp.com.


'/>"/>
SOURCE ETEX Corporation
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. MannKind Corporation to Hold First Quarter Financial Results Conference Call on May 4, 2009
2. Volcano Corporation Schedules First Quarter Conference Call, Webcast
3. WebReach, Inc. Becomes Mirth Corporation
4. Environmental Tectonics Corporation Exhibiting at the Annual Symposium on Advanced Wound Care and Wound Healing Society
5. Clarient Granted Exclusive License to Commercialize Breast Cancer Biomarker by Indiana University Research and Technology Corporation
6. GenVault Corporation Launches its Latest Centralized and Standardized Software Solution for Biobanking and Biological Sample Management, GenConnect 3.2
7. General Patent Corporation Calls New Patent Reform Bill Harmful to Inventors and Entrepreneurs
8. The Journal of Cardiac Failure Publishes Results From Celladon Corporations First-in-Human Phase 1/2 Clinical Trial in Advanced Heart Failure
9. Siemens Healthcare Announces Planned Collaboration with Harris Corporation
10. Environmental Tectonics Corporation Announces Participation at APWCA National Conference
11. Webcast Alert: Neogen Corporation Announces 3rd Quarter Results Conference Call
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/27/2016)... ... June 27, 2016 , ... Parallel 6 , the ... today the Clinical Reach Virtual Patient Encounter CONSULT module which enables both ... physician and clinical trial team. , Using the CONSULT module, patients and physicians can ...
(Date:6/27/2016)... -- Liquid Biotech USA , Inc. ... Research Agreement with The University of Pennsylvania ("PENN") ... patients.  The funding will be used to assess ... outcomes in cancer patients undergoing a variety of ... to support the design of a therapeutic, decision-making ...
(Date:6/24/2016)... 24, 2016 Epic Sciences unveiled a ... susceptible to PARP inhibitors by targeting homologous recombination ... The new test has already been incorporated into ... cancer types. Over 230 clinical trials ... pathways, including PARP, ATM, ATR, DNA-PK and WEE-1. ...
(Date:6/23/2016)... ... June 23, 2016 , ... Mosio, a leader in ... Trials Patient Recruitment and Retention Tips.” Partnering with experienced clinical research professionals, Mosio ... practical tips, tools, and strategies for clinical researchers. , “The landscape of how ...
Breaking Biology Technology:
(Date:6/2/2016)... 2, 2016 The Department of Transport ... the 44 million US Dollar project, for the , ... including Personalization, Enrolment, and IT Infrastructure , to ... production and implementation of Identity Management Solutions. Numerous renowned international ... Decatur was selected for the most compliant ...
(Date:6/1/2016)... YORK , June 1, 2016 ... Technology in Election Administration and Criminal Identification to Boost ... to a recently released TechSci Research report, " Global ... By Region, Competition Forecast and Opportunities, 2011 - 2021", ... 24.8 billion by 2021, on account of growing security ...
(Date:5/16/2016)... May 16, 2016   EyeLock LLC , a ... the opening of an IoT Center of Excellence in ... expand the development of embedded iris biometric applications. ... of convenience and security with unmatched biometric accuracy, making ... aside from DNA. EyeLock,s platform uses video technology to ...
Breaking Biology News(10 mins):